A5102027831- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Ferroptosis and cancer prognosis
- Nutrition and Health in Aging
- Genetic factors in colorectal cancer
- Renal cell carcinoma treatment
- Epigenetics and DNA Methylation
- CAR-T cell therapy research
- Pancreatic and Hepatic Oncology Research
- Immune Cell Function and Interaction
- RNA modifications and cancer
- Urologic and reproductive health conditions
- Lung Cancer Diagnosis and Treatment
- Muscle Physiology and Disorders
- Metastasis and carcinoma case studies
- Cancer Cells and Metastasis
- Endometrial and Cervical Cancer Treatments
- Exercise and Physiological Responses
- Mitochondrial Function and Pathology
- Molecular Biology Techniques and Applications
- Prostate Cancer Diagnosis and Treatment
- Cancer Research and Treatments
- CRISPR and Genetic Engineering
- Cancer-related Molecular Pathways
Nanjing Medical University
2024-2025
Jiangsu Province Hospital
2025
Shanghai Ninth People's Hospital
2023-2024
Shanghai Jiao Tong University
2024
University of Arizona
2021-2024
Army Medical University
2024
Hokkaido University
2016-2024
Shanghai Public Health Clinical Center
2024
Illumina (United States)
2016-2023
Fudan University
2023
Background Tumor mutational burden (TMB), defined as the number of somatic mutations per megabase interrogated genomic sequence, demonstrates predictive biomarker potential for identification patients with cancer most likely to respond immune checkpoint inhibitors. TMB is optimally calculated by whole exome sequencing (WES), but next-generation targeted panels provide estimates in a time-effective and cost-effective manner. However, differences panel size gene coverage, addition underlying...
•Estimation of TMB varies across different panels, with panel size, gene content and bioinformatics pipelines contributing to empirical variability.•Panel sizes greater than 667Kb are necessary maintain adequate PPA NPA for calling high versus low the range cutoffs used in practice.•Statistical calibration can achieve more consistent results panels allows comparison values various assays. BackgroundTumor mutational burden (TMB) measurements aid identifying patients who likely benefit from...
Understanding the molecular mechanisms of flowering and maturity is important for improving adaptability yield seed crops in different environments. In soybean, a facultative short-day plant, genetic variation at four genes, E1 to E4, plays an role adaptation environments with photoperiods. However, basis natural time poorly understood. Using cross between early-maturing soybean cultivars, we performed study genes. The progeny this segregated two loci, E9. latter locus was subjected detailed...
BackgroundNoninvasive genotyping using plasma cell-free DNA (cfDNA) has the potential to obviate need for some invasive biopsies in cancer patients while also elucidating disease heterogeneity. We sought develop an ultra-deep next-generation sequencing (NGS) assay with non-small-cell lung cancers (NSCLC) that could detect targetable oncogenic drivers and resistance mutations where tissue biopsy failed identify actionable alteration.Patients methodsPlasma was prospectively collected from...
Abstract Background Intratumoral heterogeneity (ITH) is a hallmark of clear cell renal carcinoma (ccRCC) that reflects the trajectory evolution and influences clinical prognosis. Here, we seek to elucidate how ITH tumor during immune checkpoint inhibitor (ICI) treatment can lead therapy resistance. Methods completed single-arm pilot study examine safety feasibility neoadjuvant nivolumab in patients with localized RCC. Primary endpoints were nivolumab. Then, spatiotemporally profiled genomic...
FLOWERING LOCUS T (FT) is an important floral integrator whose functions are conserved across plant species. In soybean, two orthologs, FT2a and FT5a, play a major role in initiating flowering. Their expression response to different photoperiods controlled by allelic combinations at the maturity loci E1 E4, generating variation flowering time among cultivars. We determined molecular basis of quantitative trait locus (QTL) for linkage group J (Chromosome 16). Fine-mapping delimited QTL...
Purpose: Tumor-derived cell-free DNA (cfDNA) in plasma can be used for molecular testing and provide an attractive alternative to tumor tissue. Commonly PCR-based technologies test limited number of alterations at the time. Therefore, novel ultrasensitive capable a broad spectrum are needed further personalized cancer therapy.Experimental Design: We developed highly sensitive ultradeep next-generation sequencing (NGS) assay using reagents from TruSeqNano library preparation NexteraRapid...
The improved survival rate of ovarian cancer (OC) is related to the action infiltrating cytotoxic T lymphocytes (CTLs). Recently, oncolytic adenoviruses (OAds) have emerged as a key player in treating solid tumors; however, immunosuppressive tumor microenvironment (TME) and body-mediated antiviral immune response limit their therapeutic effect. In this study, we tested hypothesis that bispecific T-cell engagers (BiTEs) could activate redirect CTLs increase anti-tumor effect OAds. We modified...
The high frequency of somatic copy number alterations, as opposed to point mutations, is considered a unique feature ovarian cancer. Amplification-dependent overexpression RecQ protein-like 4 (RECQL4), which participates in DNA replication and repair, mediates the development various cancers, but its pathobiological clinical roles are poorly understood. Here, using bioinformatics analysis, RECQL4 amplification was found occur 27% cancer samples TCGA cohort. be upregulated associated with...
Abstract Background As knowledge of mechanisms that drive the development cancer grows, there has been corresponding growth in therapies specific to a mechanism. While these show improvements patient outcomes, they can be expensive and are effective only for subset patients. These treatments interest research focused on assignment based aberrations individual genes or biomarkers assess broader mutational landscape, including microsatellite instability (MSI) tumor burden (TMB). Methods Here...
Immune checkpoint blockade (ICB) therapy has significantly improved clinical outcomes in bladder cancer. Identification of correlates benefit is critical to select appropriate for individual patients.
Recently, several studies have examined the association between preoperative sarcopenia and prognosis evaluation in patients with hepatocellular carcinoma (HCC) undergoing hepatectomy. However, their conclusions remain ambiguous controversial. Thus, we conducted a meta-analysis to assess prognostic role of HCC hepatectomy.We searched existing literature reporting on value computed tomography (CT)-assessed for survival The pooled hazard ratios (HRs) corresponding 95% confidence intervals...
Background and Purpose Cancer cachexia is a common cause of death among cancer patients with no currently effective treatment available. In animal models, aberrant activation STAT3 in skeletal muscle contributes to wasting. However, clinically the factors regulating molecular mechanisms involved remain incompletely understood. Experimental Approach The expression HSP90 were detected from or tumour‐bearing cachectic mice. inhibitors, including 17DMAG (alvespimycin) PU‐H71, administered...
Abstract Cancer cachexia is a multifactorial metabolic syndrome that causes up to 20% of cancer-related deaths. Muscle atrophy, the hallmark cancer cachexia, strongly impairs quality life patients; however, underlying pathological process still poorly understood. Investigation disease pathogenesis largely relies on cachectic mouse models. In our study, transcriptome gastrocnemius muscle in C26 xenograft model was integrated and compared with 5 more different datasets. The bioinformatic...
Immune checkpoint blockade (ICB) therapies display clinical efficacy in microsatellite instable (MSI) endometrial cancer (EC) treatment, the key mechanism of which is reversing T cell exhaustion and restoration anti-tumor immunity. Here, we demonstrate that transcription factor 19 (TCF19), one most significantly differentially expressed genes between MSI stable (MSS) patients The Cancer Genome Atlas (TCGA)-EC cohort, associated with poor prognosis immune signature. Specifically, TCF19...
HER2-positive (HER2
Over the past 2 decades, tumor immunotherapies have witnessed remarkable advancements, especially with emergence of immune checkpoint-targeting bispecific antibodies. However, a quantitative understanding dynamic cross-talking mechanisms underlying different checkpoints as well optimal dosing and target design antibodies still remain challenging to researchers. To address this challenge, we here developed multi-scale systems pharmacology (QSP) model platform that integrates diverse array...
To identify the plasma protein biomarkers related to chemoresistance of postoperative recurrence epithelial ovarian cancers. Forty samples from patients in chemotherapy-sensitive and chemotherapy-resistant groups (20 for each group) were collected at Gynecology Department Fourth Hospital Hebei Medical University September 2013 2014. The differentially expressed proteins between two screened with two-dimensional gel electrophoresis (2-DE) further analyzed by matrix-assisted laser...
2624 Background: Tumor mutational burden (TMB) is a predictive biomarker of response to immune checkpoint inhibitors across multiple cancers. In Phase 1 the Friends Cancer Research Harmonization Project, we demonstrated robust correlation between TMB estimated using targeted next-generation sequencing (NGS) gene panels and whole exome (WES) applied MC3-TCGA data. These findings variability in estimates different panels. 2 evaluates sustainable reference standard materials for alignment...
Pancreatic ductal adenocarcinoma (PDAC) represents one of the deadliest forms cancer with very few available therapeutic options. We previously reported that an engineered human enzyme, cyst(e)inase, which degrades L-cysteine (L-Cys) and cystine, inhibits growth multiple cells, including PDAC both in vitro vivo. Here, we show cyst(e)inase treatment leads to increased clustered oxidative DNA damage, single-strand breaks, apurinic/apyrimidinic sites, double-strand breaks (DSBs) cells sensitive...